93 results about "Salmonella escanaba" patented technology

The invention discloses an antibacterial peptide and application thereof, and belongs to the technical field of biology. The antibacterial peptide with an inhibition effect on various clinically common pathogenic microorganisms is obtained, and the antibacterial peptide comprises gram-negative bacteria such as escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, vibrio parahaemolyticus, salmonella gallinarum, salmonella typhimurium and enterobacter sakazakii, and gram-positive bacteria. The antibacterial peptide provided by the invention can be used as an antibacterial peptide, such as staphylococcus aureus, listeria monocytogenes and bacillus cereus, and the antibacterial peptide provided by the invention is novel in structure and easy to prepare.

The invention discloses a polypeptide drug for resisting gram-negative bacteria and application, and belongs to the technical field of biological medicine. The MIC of the antibacterial peptide obtained through screening on escherichia coli, salmonella typhimurium, pseudomonas aeruginosa, klebsiella pneumoniae, shigella sonnei and stenotrophomonas maltophilia is 16 [mu] g / mL, 2 [mu] g / mL, 16 [mu] g / mL, 4 [mu] g / mL, 2 [mu] g / mL and 4 [mu] g / mL respectively, and the antibacterial peptide has broad-spectrum antibacterial performance. The hemolytic activity and toxicity of the compound are lower than therapeutic concentration threshold values, and the compound can be used for preparing drugs or medical products for treating multi-drug-resistant bacterium infection.

The invention discloses a bacteriophage lyase and application thereof, and particularly relates to a bacteriophage lyase with an amino acid sequence as shown in SEQ INNO.2. The bacteriophage lyase can inhibit the growth of escherichia coli, staphylococcus and salmonella, can be used as an antibacterial substance in splitting gram-negative bacteria and can be used for preparing drugs for resisting gram-negative bacteria. The lyase can be used independently or compounded with other substances, the use concentration of antibiotics can be reduced by combining the lyase with the antibiotics, toxic and side effects (such as renal toxicity of polymyxin) of drugs are reduced, and meanwhile, generation of bacterial drug resistance is delayed. After the lyase and the chitosan are combined for use, remarkable antibacterial activity is generated, the antibacterial effect can be achieved without pre-treatment on bacteria, and the practicability is improved.

The present disclosure provides compositions and methods for making and using Salmonella recombinant bacteria that express LPS O78 antigen and / or virulence factors of avian pathogenic Escherichia coli (APEC) as vaccines to prevent colibacillosis infections.

The invention discloses bifidobacterium breve with hypoglycemic capacity and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides a bifidobacterium breve (Bifidobacterium breve) strain BBr37 with the blood sugar reducing capacity, and the preservation number of the bifidobacterium breve strain BBr37 is CGMCC (China General Microbiological Culture Collection Center) NO.32423. The invention also provides an application of the strain BBr37 in preparation of hypoglycemic drugs or health-care foods with an auxiliary hypoglycemic function or bacteriostatic agents or non-treatment-destination bacteriostasis, and a product and a method based on the strain BBr37. The strain BBr37 disclosed by the invention has a relatively strong inhibition effect on escherichia coli, staphylococcus aureus, salmonella, haemophilus parasuis, haemophilus parainfluenza, campylobacter jejuni and enterocolitis yarrowia, and can effectively achieve the effects of reducing blood sugar and regulating intestinal flora.

The present invention discloses a Bacillus velezensis GY1, which was deposited in the Guangdong Provincial Microbial Culture Collection Center on June 28, 2024, with a deposit number of GDMCC No: 64792. The Bacillus velezensis GY1 provided by the present invention can degrade 100% and 56.4% of nitrogen in M9 culture medium containing 200 mg / L and 1000 mg / L ammonia nitrogen, respectively, and the ammonia reduction rate in the actual production of aquaculture water reaches 53.3%. It also has a strong inhibitory effect on common pathogens in aquatic products: Vibrio alginolyticus, Salmonella and Vibrio parahaemolyticus.

The invention belongs to the technical field of microorganisms, and discloses a phage capable of efficiently splitting escherichia coli and salmonella, a preparation and application of the phage, the name is SP1, the classification name is escherichia coli phage, the preservation number is CGMCC No.46440, the preservation date is China General Microbiological Culture Collection Center on May 30, 2025, and the preservation unit is China General Microbiological Culture Collection Center. The optimal infection complex number of the bacteriophage is 1, the bacteriophage has very strong acid resistance and thermal stability, and the bacteriophage can keep high titer under the conditions that the pH value is 4-11, the temperature is 10-70 DEG C and the ultraviolet irradiation is within 30 minutes. The incubation period of escherichia coli infected by the bacteriophage is about 30 min, the outbreak period is about 40 min after the incubation period, and the bacteriophage can specifically split escherichia coli and salmonella, does not contain virulence and drug-resistant genes and is high in biological safety.

The invention discloses an enterococcus faecalis bacteriophage vBEfaPFA2, a bacteriophage composition and application of the enterococcus faecalis bacteriophage vBEfaPFA2, the enterococcus faecalis bacteriophage vBEfaPFA2 has a specific lysis effect on enterococcus faecalis and also has a cross-species lysis effect on salmonella, the acid-base adaptability of the bacteriophage is high, and the bacteriophage vBEfaPFA2 and the bacteriophage composition can be used for preparing the enterococcus faecalis bacteriophage The enterococcus faecalis bacteriophage can be used as an active component to be prepared into the bacteriophage composition or the bacteriophage pharmaceutical preparation, the bacteriophage composition or the bacteriophage pharmaceutical preparation is applied to preparation of a medicine or a bacteriostatic agent for preventing and treating enterococcus faecalis and salmonella infection, the enterococcus faecalis bacteriophage and the bacteriophage composition are safe to use, high in yield and easy to industrially produce, and due to the cross-species lysis performance, the bacteriophage can be The method has the advantages of wide splitting spectrum, wide application range and good application prospect.

The invention discloses bacillus subtilis for recombinant expression of a hermetia illucens HIAMP0438 gene and a construction method of the bacillus subtilis, and belongs to the technical field of gene engineering. The hermetia illucens recombinant protein used in the invention is obtained by expression of bacillus subtilis WB800N transferred into a pHT43-HIAMP0438 high-efficiency expression vector, and the pHT43-HIAMP0438 high-efficiency expression vector is obtained by a homologous recombination technology, so that high-level expression of the HIAMP0438 gene is realized, the HIAMP0438 gene can be efficiently secreted out of cells, the preparation process of the recombinant protein is greatly simplified, and the production cost is reduced. According to the present invention, the recombinant protein can significantly inhibit the growth of Escherichia coli, Salmonella and Listeria monocytogenes, and the recombinant protein can be used as the animal health product, and can be used for preventing and treating pig and chicken intestinal diarrhea caused by Escherichia coli and Salmonella and food-borne digestive tract diseases caused by Listeria monocytogenes.

The present invention provides compositions and methods of inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella typhi vector comprising a heterologous antigen from a pathogen, wherein the heterologous antigen comprises an outer membrane protein, an antigenic fragment thereof or a variant thereof, wherein the antigen is delivered to a mucosal tissue of the subject by an outer membrane vesicle.

The invention provides a cyclic oligopeptide. The oligopeptide provided by the invention has an obvious inhibiting effect on lymphoma, leukemia, breast cancer, lung cancer, liver cancer or myeloma, has a certain inhibiting effect on escherichia coli, staphylococcus aureus, pseudomonas aeruginosa and salmonella paratyphi B, and also has a certain uric acid reducing effect. Therefore, the compound has great significance in preparation of antitumor drugs, antibacterial drugs and uric acid reducing drugs.

The invention relates to the technical field of microorganisms, in particular to a lactobacillus plantarum strain LS2 and application thereof.The lactobacillus plantarum strain LS2 is separated from cheese, has the high GABA production capacity and the nitrite degradation capacity, has the antibacterial effect on enteric pathogenic bacteria including escherichia coli, salmonella enteritidis and campylobacter jejuni, and has the advantages that the lactobacillus plantarum strain LS2 is high in GABA production capacity and nitrite degradation capacity; the strain has good antibacterial function, good acid resistance and cholate resistance, and can well survive in artificial intestinal juice and artificial gastric juice; in order to improve the yield of GABA, the accelerant capable of remarkably promoting the growth of the strain LS2 is obtained by researching the accelerant, the highest survival rate of the freeze-dried powder prepared by optimizing the accelerant and the freeze-dried powder can reach 99% or above, the nitrite degradation rate can reach 98% or above, the yield of GABA is improved to 3.3 g / L or above, and the freeze-dried powder is bacterial powder capable of being widely applied.

The invention provides chitosan coupled polypeptide and a preservative film prepared from the chitosan coupled polypeptide, active peptide used for preparing the preservative film has good antibacterial activity on escherichia coli, salmonella, staphylococcus aureus and drug-resistant escherichia coli, and the amino acid sequence of the active peptide is SEQ ID NO: 1. The preservative film prepared by coupling the active peptide and the chitosan provided by the invention has remarkable antibacterial activity, also has good resistance to drug-resistant strain drug-resistant escherichia coli, is good in mechanical property, air permeability, moisture penetrability and stability, and is suitable for being used in the fields of food preservation, medical dressing and the like.

The invention discloses a colorimetric-fluorescence dual-mode detection method for salmonella and escherichia coli, and belongs to the technical field of biological detection. According to the invention, concanavalin A (ConA) is coupled with magnetic nanoparticles (MNPs) to form MNPs (at) ConA as a capture probe by recognizing the characteristic of capturing bacteria by sugar residues, and in addition, an antibody (Ab) can specifically recognize bacteria and is coupled with quantum dots (QDs) to form QDs (at) Ab as a fluorescence signal probe. The invention finds that MNPs can catalyze 3, 3 ', 5, 5'-tetramethyl benzidine (TMB) to generate blue oxTMB which can be observed by naked eyes; and the QDs have strong fluorescence and can also be observed by naked eyes, so that obvious distinguishing is realized in Sal and Esc detection. And the signal is linearly related to the target bacteria, so that the visibility is good. The practicability of the method is verified by detecting milk tea, milk and fruit juice samples, and the recovery rate is 93.5-106%. The feasibility of detecting Sal and Esc by the method is verified, and the method has important application potential in food safety monitoring.

The invention provides a preparation method and application of alpinia oxyphylla leaf essential oil, and relates to the field of natural plant extracts. The alpinia oxyphylla leaf essential oil is applied to preparation of a bacteriostatic agent for inhibiting bacteria or / and fungi, and the bacteria comprise one or more of klebsiella pneumoniae, salmonella enterobacter and shigella flexneri. The fungi comprise one or more of candida tropicalis and malassezia furfur; the preparation method of the alpinia oxyphylla leaf essential oil comprises the following steps that alpinia oxyphylla leaves are taken, dried and smashed, the smashed alpinia oxyphylla leaves are placed in water to be soaked, the material-liquid mass ratio is 1: (15-17), and the soaking time is 0.8-1.2 h; after soaking, distillation is carried out, the distillation time is 4.5-5.5 h, and the distillation temperature is 170-200 DEG C; and after distillation is finished, collecting upper oily liquid to obtain the alpinia oxyphylla leaf essential oil. The prepared alpinia oxyphylla leaf essential oil has broad-spectrum antibacterial and bactericidal effects, and the antibacterial and bactericidal effects are good.

The invention relates to small molecule compounds that are useful as antimicrobial agents, pharmaceutical compositions comprising the compounds, and the use of the compounds in the treatment of subjects with microbial infections.

The invention relates to the technical field of agricultural biology, in particular to an alpha spiral mutant of granulysin with improved antibacterial activity and application of the alpha spiral mutant. The amino acid sequence of the alpha spiral mutant peptide of granulysin with improved antibacterial activity is as shown in SEQ ID No: 2. According to the present invention, the antibacterial activity of the granulysin mutant on different bacteria such as gram-negative bacteria salmonella typhimurium, escherichia coli and salmonella pullorum is enhanced;

The present invention discloses a recombinant Escherichia coli capable of producing a monophosphate lipid A vaccine adjuvant, belonging to the fields of genetic engineering and synthetic biology. The present invention knocks out the mlaE and pldA genes of the phospholipid transport system on the Escherichia coli MG1655 genome, the hns gene that regulates PagP expression, and sequentially integrates the FnlpxE gene from Francisella and the SepagL gene from Salmonella by deletion and replacement of other phospholipid transport-related gene clusters ybgC-cpoB and letAB, thereby obtaining the recombinant bacterium WZM012. Through simple fermentation, the WZM012 strain can efficiently synthesize hexaacylated monophosphate lipid A (MPL), producing 32.76 mg / L of MPL in 24 hours of fermentation, with the proportion of MPL in the total lipid A reaching 70%.

The invention belongs to the field of biotechnology and medical preparations, and provides a yeast microcapsule delivery BBR / EGCG probiotic preparation and application thereof. The probiotic Nissle1917 and the anti-inflammatory and anti-oxidation natural products BBR and EGCG are packaged by adopting the yeast membrane, so that the probiotic Nissle1917 has good tolerance and cell targeting property, is easy to colonize in intestinal tracts and exert anti-inflammatory and mucous membrane repairing functions, particularly has a better treatment effect on enteritis caused by salmonella typhimurium, and has a wide application prospect. The problem that an existing probiotic agent is poor in bacterial enteritis treatment effect is solved.

The application belongs to the technical field of biology, and discloses a preparation method of a Salmonella typhimurium flagellin and Senecavirus antigen fusion protein. The application selects Escherichia coli Rosetta (DE3) as a host, fuses a Salmonella typhimurium flagellin gene and a Senecavirus antigen gene, optimizes codons, and then clones the fusion protein into a pET-28a (+) vector, so that the obtained fusion protein can keep the adjuvant activity of the flagellin, improve the solubility and expression level of VP2, and the yield can reach 40 mg / L, thereby greatly reducing the expression and purification process cost. The fusion protein provided by the application can activate the TLR5 path and activate mouse macrophages, and the production process is simple and low in cost, so that the application has important significance for the research and production of Senecavirus subunit vaccines.

The present invention discloses a strain of poultry-derived Salmonella typhimurium ST0602 and its application. The strain has been preserved, and the preservation unit is: China Center for Type Culture Collection; address: Wuhan University; preservation date: May 30, 2024; preservation number: CCTCC NO.M 20241100. The present invention also provides the application of the Salmonella typhimurium for constructing a poultry attenuated vaccine strain. Salmonella typhimurium ST0602 is sensitive to currently common antibacterial drugs and has good genetic stability, and is suitable for constructing a live attenuated vaccine strain of Salmonella typhimurium.

Provided is use of a combination of three or more of the following microorganisms in the preparation of an anti-tumor combination vaccine: Bordetella pertussis, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Staphylococcus aureus, Listeria monocytogenes, Escherichia coli, Proteusbacillus vulgaris, Lactic acid bacteria, Bifidobacterium longum, Bordetella pertussis, Corynebacterium diphtheriae and Clostridium tetani, Clostridium acetobutylicum, Salmonella typhimurium, and Streptococcus pyogenes. The anti-tumor combination vaccine is broad-spectrum, safe and non-toxic, and thus has the prospect of clinical applications.

The invention relates to the technical field of agricultural biology, in particular to an antibacterial peptide chicken NK lysin mutant and application thereof. According to the present invention, the antibacterial activity of the chicken NK lysin mutant on different bacteria such as salmonella typhimurium 541, gram-negative bacteria, Escherichia coli O157: H7 1491, gram-negative bacteria, salmonella pullorum of gram-negative bacteria, and Staphylococcus aureus can be enhanced, and the antibacterial activity of the chicken NK lysin mutant on different bacteria such as salmonella typhimurium 541, gram-negative bacteria, Escherichia coli O157: H7 1491, gram-negative bacteria, salmonella pullorum of gram-negative bacteria, and Staphylococcus aureus can be enhanced;

The invention discloses a lactobacillus acidophilus LAHuBR15 and an application of the lactobacillus acidophilus LAHuBR15. The preservation number of the lactobacillus acidophilus LAHuBR15 is CCTCC (China Center for Type Culture Collection) NO: M 20241050, and the preservation number of the lactobacillus acidophilus LAHuBR15 is CCTCC NO: M 20241050. The lactobacillus acidophilus LAHuBR15 disclosed by the invention has the capability of inhibiting salmonella in vivo, and shows excellent stress resistance characteristics of high temperature resistance, gastric acid resistance, cholate resistance and digestive enzyme resistance.

The invention relates to a salmonella enteritidis bacteriophage, which is named as PAC / QD23121802, and the preservation number of the salmonella enteritidis bacteriophage is CGMCC No.46089. The salmonella enteritidis bacteriophage PAC / QD23121802 is in the form that the head part is of a 24-face structure, the length of the head part is 750-800nm, and the length of the tail part is 300-350nm. The invention also discloses a salmonella bacteriophage composition, wherein the salmonella bacteriophage composition contains the salmonella bacteriophage PAC / QD23121802 and the salmonella bacteriophage PAC / QD23120510. The invention also discloses a salmonella bacteriophage composition, the composition has wide spectrum, experimental data show that the composition can kill 100% salmonella enteritidis, and the bacteriophage composition has the advantage of enhancing the treatment effect of the bacteriophage. The genomes of the bacteriophage of the composition do not carry virulence genes, drug-resistant genes and lysogenic genes, so that the transmission of the virulence genes and the drug-resistant genes is not caused, and the use is safe.

The application discloses an Escherichia coli bacteriophage capable of cross-species lysis and an application thereof, and belongs to the technical field of bacteriophages. The Escherichia coli bacteriophage vB_E.coli P_SD29 provided by the application has been preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC No.47023. Experimental results show that the Escherichia coli bacteriophage vB_E.coli P_SD29 can lyse 11 strains of Escherichia coli and 2 strains of Salmonella from different poultry sources, has a large lysis amount, and can maintain activity in an environment of 4-65 DEG C and pH=3-12, and the genome does not contain genes coding for virulence or drug resistance. The application provides a broad-spectrum bacteriophage with a wide host spectrum, strong lysis, stable properties and no potential safety risks for preventing and controlling Escherichia coli and Salmonella in poultry breeding production.

The invention discloses a flora for treating industrial wastewater and application of the flora for treating the industrial wastewater or polluted soil, the flora comprises stenotrophomonas and at least two selected from the group consisting of comamonas, ochrobactrum, pseudomonas, brucella, citrobacter, salmonella, balloon and enterococcus, and wherein the industrial wastewater contains a bactericide.

This invention relates to the field of agricultural biotechnology, specifically to the antimicrobial peptide chicken NK lysin mutant and its applications. The chicken NK lysin mutant of this invention is effective against various bacteria, such as Salmonella typhimurium (…). Salmonella typhimurium 541, Gram-negative bacteria), Escherichia coli ( Escherichia coli O157:H7 1491, Gram-negative bacteria), Gram-negative bacteria Salmonella pullorum ( salmonella pullorum ) and Staphylococcus aureus ( Staphylococcus aureus The antibacterial activity of ) is enhanced.

The invention relates to the technical field of natural antibacterial compounds, in particular to an antibacterial compound, a preparation method and application thereof and a pesticide agent. The antibacterial compound is selected from compounds shown in the following structural formula: the compound has an inhibition effect on methicillin-resistant staphylococcus aureus and other drug-resistant bacteria, staphylococcus aureus, escherichia coli, salmonella, pseudomonas aeruginosa and other bacteria, and alternaria, fusarium, colletotrichum and other fungi; the compound can be applied as broad-spectrum antibacterial, broad-spectrum antifungal and drug-resistant bacterium resistant drugs.

The present invention relates to identifying and engineering a tail spike protein gene from a genome of bacteriophage SFP10 infected with a Salmonella strain, purifying and producing a recombinant protein using mSFP10TSP, which is a recombinant protein formulation for detecting Salmonella enterica, EGFP-mSFP10TSP fused with a green fluorescent protein, and SiBD-mSFP10TSP fused with an SiBD, and thereby specifically detecting the Salmonella strain.